A fragment can share part of a peptide’s sequence without sharing all of its behaviour. Thymosin beta-4 is a useful example because both the intact molecule and selected fragments have been tested in actin-related experiments. This guide establishes the full-length reference and shows how a direct comparison can prevent unsupported transfer of findings to shorter materials.
Establish the intact reference first
Low, Hu and Goldstein’s 1981 sequence paper described thymosin beta-4 isolated from calf thymus as a 43-residue peptide with an acetyl-blocked amino terminus. This gives the full-length molecule a defined reference beyond the informal word thymosin.Low, Hu and Goldstein — Complete sequence of bovine thymosin beta 4 (opens in a new tab)
The reference must include terminal chemistry as well as residue count. A shortened sequence, an oxidised residue or a changed terminal group should be recorded explicitly rather than absorbed into the same label.
A sequence interval also needs a stated numbering system. Residue 13 of the mature peptide is not necessarily residue 13 of a longer translated precursor record.
For a fragment comparison, keep a copy of the reference sequence and mark exactly which residues are retained. Record any new terminal groups separately: cutting a segment creates ends that did not exist at those positions in the intact chain.
What actin sequestration means in the original comparison
Safer, Elzinga and Nachmias connected the platelet peptide previously called Fx to thymosin beta-4 through sequence and functional comparisons. The intact peptide formed a 1:1 complex with actin monomers and inhibited their salt-induced polymerisation in the experimental system.Safer, Elzinga and Nachmias — Thymosin beta 4 and Fx (opens in a new tab)
This is a specific molecular interaction and assay outcome. It does not mean that every actin-related process in a living organism will change in the same direction.
It also does not establish a clinical tissue-repair outcome. A binding relationship can motivate a research hypothesis while leaving questions about distribution, cellular context and organism-level effects unresolved.
Direct fragment testing can overturn a simple assumption
Hannappel and Wartenberg tested intact thymosin beta-4 and selected fragments using a DNase I-based actin assay. The 13–43 and 24–43 fragments did not inhibit actin polymerisation as the intact peptide did.Hannappel and Wartenberg — Actin-sequestering ability of thymosin beta 4 and fragments (opens in a new tab)
Those fragments retain substantial parts of the parent sequence. Their different result shows why shared sequence alone is not enough to inherit a full-length functional claim.
| Material | Residues retained | Reading consequence |
|---|---|---|
| Intact reference | 43 | The parent result belongs here |
| Fragment 13–43 | 31 | Missing residues can change the measured activity |
| Fragment 24–43 | 20 | A shorter retained region needs direct testing |
The fragment lengths use inclusive counting: last position minus first position plus one. These calculations describe sequence coverage, not a percentage of biological potency.
The same study found that oxidation of the methionine at position 6 did not abolish the measured actin-sequestering property. That result is limited to that modification and assay; it is not permission to assume that all chemical changes are functionally harmless.Hannappel and Wartenberg — Actin-sequestering ability of thymosin beta 4 and fragments (opens in a new tab)
Apply the reference to a new paper or product name
First classify the material as full length, a specified fragment or an incompletely described preparation. Then identify the exact assay and comparator supporting its claimed activity.
If a paper tested the intact molecule but a supplied material is shorter, record the paper as parent-molecule context. Do not quietly move its result into the fragment’s evidence column.
If the supplied material’s identity is unresolved, that uncertainty comes before an efficacy summary. A familiar catalogue name is not a substitute for the sequence, terminal chemistry and reference specification.
A useful evidence record can show both relationships: how the fragment maps onto the parent and what has actually been measured for the fragment itself. Keeping these separate makes the reference informative without making it a product-equivalence claim.
Sources and further detail
- Low, Hu and Goldstein — Complete sequence of bovine thymosin beta 4 (opens in a new tab)
Original 1981 abstract read for 43-residue length and N-terminal acetylation. Historical activity descriptions are not extended to modern clinical claims.
- Safer, Elzinga and Nachmias — Thymosin beta 4 and Fx (opens in a new tab)
Original 1991 abstract read for identity comparison, monomer complex and polymerisation assay. No clinical tissue-repair conclusion inferred.
- Hannappel and Wartenberg — Actin-sequestering ability of thymosin beta 4 and fragments (opens in a new tab)
Original 1993 abstract and author metadata read. Fragment-negative and methionine-oxidation results retained; sequence lengths are original arithmetic.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.